These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9471)

  • 21. A review of brief medication-adherence instruments used in patients with schizophrenia and bipolar disorder.
    Pomykacz B; Mao M; Weiss RD; Teter CJ
    Harv Rev Psychiatry; 2007; 15(5):259-63. PubMed ID: 17924260
    [No Abstract]   [Full Text] [Related]  

  • 22. Antipsychotic medication and length of stay at a psychiatric maximum-security unit in Norway (1987-2000).
    Renkel S; Rasmussen K
    Nord J Psychiatry; 2006; 60(2):132-6. PubMed ID: 16635932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term prospective comparison of prepulse inhibition between schizophrenic patients and healthy controls.
    Preuss UW; Zimmermann J; Watzke S; Langosch J; Siafarikas N; Wong JW; Hamm A; Weike A
    Pharmacopsychiatry; 2011 May; 44(3):102-8. PubMed ID: 21432751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of abstractive and nonabstractive deficits in schizophrenics and psychiatric controls.
    Watson CG; Wold J; Kucala T
    J Nerv Ment Dis; 1976 Sep; 163(3):193-9. PubMed ID: 956803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of antipsychotic medication on the linguistic ability of schizophrenics.
    Hymowitz P; Spohn H
    J Nerv Ment Dis; 1980 May; 168(5):287-96. PubMed ID: 6102593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of neuroleptic dosage and extrapyramidal side effects on schizophrenic basic symptoms.
    Moritz S; Krausz M; Gottwalz E; Andresen B
    Compr Psychiatry; 2000; 41(4):284-8. PubMed ID: 10929797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancing medication use in schizophrenic patients.
    Diamond RJ
    J Clin Psychiatry; 1983 Jun; 44(6 Pt 2):7-14. PubMed ID: 6133855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reply to comments on "Optimizing early prediction for antipsychotic response in schizophrenia".
    Chang YC; Lane HY
    J Clin Psychopharmacol; 2009 Aug; 29(4):391. PubMed ID: 19593183
    [No Abstract]   [Full Text] [Related]  

  • 30. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing symptom response among antipsychotic medications in CATIE.
    Levine SZ; Rabinowitz J; Ascher-Svanum H; Faries DE; Lawson AH
    J Clin Psychopharmacol; 2013 Feb; 33(1):123-6. PubMed ID: 23288232
    [No Abstract]   [Full Text] [Related]  

  • 32. Relationship between neuroleptic dose and positive and negative symptoms.
    Johnson PB; Ramirez PM; Opler LA; Malgady R
    Psychol Rep; 1994 Apr; 74(2):481-2. PubMed ID: 7910976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
    Johnson DA
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Saccadic hypometria in drug-naive and drug-treated schizophrenic patients: a working memory deficit?
    Hutton SB; Cuthbert I; Crawford TJ; Kennard C; Barnes TR; Joyce EM
    Psychophysiology; 2001 Jan; 38(1):125-32. PubMed ID: 11321613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving treatment adherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2011 Sep; 72(9):e28. PubMed ID: 21951990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic alliance, a stake in schizophrenia].
    Charpentier A; Goudemand M; Thomas P
    Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Configuration frequency analysis. XI. Strategies of symptom configuration comparison before and after therapy].
    Lienert GA; Straube E
    Z Klin Psychol Psychother; 1980; 28(2):110-23. PubMed ID: 6108653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Documenting informed consent for antipsychotic medication.
    Holzapfel S
    Can Fam Physician; 1999 Jun; 45():1403-4, 1415-6. PubMed ID: 10386200
    [No Abstract]   [Full Text] [Related]  

  • 39. [Various aspects of cognitive activities of schizophrenics. III. Maladjustment assimilation/accommodation and generalization of reasoning].
    Blein G; Azorin JM; Vollrath JL; Andréoli A; Tissot R
    Ann Med Psychol (Paris); 1987 May; 145(5):409-26. PubMed ID: 3688697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Stroop test and schizophrenia].
    Grapperon J; Delage M
    Encephale; 1999; 25(1):50-8. PubMed ID: 10205734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.